Scientists of the University of Sirius are working on the creation of a new class of drugs for diabetes of the 2nd type and obesity. Unlike existing foreign analogues, the Russian drug will be produced in the form of tablets, not injections.
The development is based on compounds affecting glucagonopian peptide-1 (GLP-1)-a natural molecule that regulates blood sugar and appetite. Scientists modified the structure of the foreign drug Danuglipron, which previously showed serious side effects in clinical trials.
So far, substances are tested only on cell cultures. After choosing the most promising option, researchers plan to move on to preclinical and clinical trials.
Earlier, specialists from the Ural Federal University, the Institute of Organic Synthesis of the Ural Branch of the Russian Academy of Sciences and the Volgograd Medical University Developed New compounds to combat the serious consequences of diabetes of the second type.
